Latest Conference Articles

The inaugural DermVIP Summit will be held from May 8 to 9 at the New York Academy of Medicine.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Hope Mitchell, MD, shared practical strategies for protecting and cultivating an online presence at the 2026 American Academy of Dermatology Annual Meeting.

Patricia M. Delgado, DNP, AGPCNP, DCNP, PMHNP, and Mohammad Jafferany, MD, discuss how integrating mental health and dermatologic care can improve outcomes for patients with chronic skin conditions.

AAD honors Henry W. Lim, MD, FAAD, with the Academy's highest honor for his work in photodermatology advances, skin of color care, and global leadership.

Steven Daveluy, MD, reviews long-term trial data for bimekizumab in psoriasis and hidradenitis suppurativa presented at the 2026 AAD Annual Meeting.

Explore top dermatology conferences and meetings in April 2026 and let us know which ones you'll be attending!

Kimball presented new data on MoonLake Immunotherapeutics’ sonelokimab and reflected on other HS updates presented at AAD 2026.

Daniel C. Butler, MD, discusses the underrepresentation of older adults in dermatology trials and what a 3-system framework for itch means for clinical practice

The combination therapy SHORE trial produced the highest response rates of the 3 studies, with EASI-75 approaching 48% in the Q4W arm.

Liza O'Dowd, MD, discusses the drug's long road to FDA approval and what its oral delivery means for patients with plaque psoriasis.

At AAD 2026, Andrew Blauvelt, MD, presented robust PASI responses and favorable safety from ONWARD1 and ONWARD2 trials of envudeucitinib, a next-generation TYK2 inhibitor.

With so many new options in dermatology, personalized medicine may be replacing guideline-driven care.

At AAD 2026, Christopher Bunick, MD, PhD, and David Cotter, MD, PhD, discuss data suggesting tirzepatide may augment ixekizumab responses in psoriatic arthritis—potentially independent of weight loss.

Catch up on coverage from the fourth day of the 2026 American Academy of Dermatology Annual Meeting held in Denver, Colorado.

Posters from Allergan Aesthetics highlight the efficacy of investigational trenibotulinumtoxinE, along with new aesthetic trends in GLP-1 users.

The small protein therapeutic gave hidradenitis suppurativa patients greater reductions in inflammatory lesion counts after 32 weeks.

Jeff Yu, MD, discusses important issues in screening and addressing pediatric contact dermatitis at the AAD Annual Meeting.

Christopher Bunick, MD, PhD, and Chinweike Ukomadu, MD, PhD, discuss late-breaking phase 3 findings at AAD highlighting high rates of clearance and favorable safety with once-daily oral zasocitinib.

At AAD 2026, Maria-Angeliki Gkini, MD, PhD, shared guidance on diagnosing and managing topical steroid withdrawal syndrome.

Three-year BE HEARD EXT data confirm that bimekizumab's clinical responses deepen over time, with HiSCR90 rates rising from 42% at year 1 to 64% at year 3.

At AAD 2026, Todd Schlesinger, MD, highlighted how staging frameworks and clinicopathologic features can inform treatment decisions in nonmelanoma skin cancer.

Catch up on coverage from the third day of the 2026 American Academy of Dermatology Annual Meeting held in Denver, Colorado.

At AAD 2026, Christopher Bunick, MD, PhD, and Reid Waldman, MD, discuss investigational VDPHL01, extended-release oral minoxidil, for the treatment of women and men with pattern hair loss.

Liza O'Dowd, MD, shared insights on the latest data on icotrokinra at the AAD Annual Meeting.

LEO Pharma presented 3 AAD posters on the efficacy of tralokinumab in various AD subgroups across the 12-month TRACE program.

New sunscreen filters, AI tools, and immunotherapies are reshaping skin cancer prevention and treatment, improving precision and long-term survival.

During the late-breaking research session at the 2026 AAD Annual Meeting 2026, Mary Spellman, MD, shared successful news about intratumoral PH762 for cutaneous carcinomas.